MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
49.74
-3.56
-6.68%
Opening 12:00 12/16 EST
OPEN
48.00
PREV CLOSE
53.30
HIGH
52.50
LOW
45.25
VOLUME
3.02M
TURNOVER
--
52 WEEK HIGH
66.92
52 WEEK LOW
6.48
MARKET CAP
1.01B
P/E (TTM)
-6.2752
1D
5D
1M
3M
1Y
5Y
1D
Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion
Benzinga · 5h ago
Nektar price target raised to $115 from $98 at Oppenheimer
TipRanks · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-ADP, Bunge, Sunrun
Reuters · 6h ago
BUZZ-Nektar falls after autoimmune disorder drug misses main goal in mid-stage study
Reuters · 8h ago
NEKTAR THERAPEUTICS SHARES DOWN 2.4% PREMARKET AFTER ITS AUTOIMMUNE DISORDER DRUG MISSES MAIN GOAL IN MID-STAGE STUDY
Reuters · 8h ago
Nektar Therapeutics Announces Phase 2b Trial Results
TipRanks · 8h ago
Nektar rises after mid-stage trial data for lead asset in hair loss disorder
Seeking Alpha · 9h ago
NEKTAR THERAPEUTICS - BOTH REZPEGALDESLEUKIN TREATMENT ARMS MET STATISTICAL SIGNIFICANCE EXCLUDING VIOLATIONS
Reuters · 9h ago
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.